RecruitingPhase 2

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

United States51 participantsStarted 2024-12-02

Plain-language summary

This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels of cancer survivors with cancer related cognitive impairment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and/or other breast cancer interventions
✓. Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years
✓. Non-breast cancer patients exposed to other anticancer therapies within the past 3 years

What they're measuring

Change in circulating Brain-Derived Neurotrophic Factor (BDNF) levels over time in cancer survivors experiencing cognitive impairment (CRCI)

Timeframe: 8 weeks

Trial details

NCT IDNCT06580002

SponsorUniversity of California, Irvine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

Contact for this trial

Chao Family Comprehensive Cancer Center University of California, Irvine

1-877-827-8839 ucstudy@uci.edu

View on ClinicalTrials.gov More Breast Cancer trials